fashion -WSS

fashion

author：comprehensive 2025-09-29 20:17:30 - browse：882

MODERNA - Norwood facility — Alex Hogan/STAT

Moderna announced Monday that, in a Phase 3 clinical trial, its combination Covid-19 and influenza vaccine generated stronger immune responses in older adults than individual vaccines that target those viruses.

The findings, disclosed in a press release, suggest the company may be on track to bring a combination flu and Covid vaccine to the market, potentially as early as autumn 2025.

“We’re excited to move forward in our discussions with regulators, and hopefully continue to help address respiratory viruses globally,” Moderna President Stephen Hoge told STAT in an interview in which he acknowledged that the fall 2025 vaccine rollout is a target the company would like to hit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： What a koala virus tells us about the human genome

hotspot

WSS

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Vertex non

Obesity drug from Roche shows promise in early study

White House pharmacy plagued with problems, investigation finds

Boston competes with Raleigh

Venture capital firm's plans to take over Akron hospital face hurdles

leisure time

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Abbott's new stent may help patients with peripheral artery disease

In Memoriam: Notable people who died in 2023

Vertex non

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

ALS treatment from Biogen, Ionis fails in study

Duchenne breakthrough therapy leaves behind pioneering families

As H5N1 spreads in cows, experts warn against drinking raw milk

Cancer drug shortages should be causing more outrage

Boston competes with Raleigh

leisure time

Abbott's new stent may help patients with peripheral artery disease

Oak Street deal isn't the answer to health care's woes

Investment in vaccine development is lagging, report finds

How generative AI ratchets up security threats for health systems

Why Medicare shouldn’t cover every FDA

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

hotspot

hotspot

focus

focus